Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 11/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756737 | 0.83 | NPY5R (0.48) | NPY5RANO1TP53MDM2MEN1 | |
| SCHEMBL1954283 | 0.82 | ANO1 (0.53) | ANO1MEN1KMT2A | |
| SCHEMBL12756744 | 0.81 | P2RX7 (0.40) | NPY5RANO1TP53MDM2MEN1 | |
| SCHEMBL12830909 | 0.80 | ANO1 (0.38) | NPY5RANO1TP53MDM2 | |
| SCHEMBL12756733 | 0.79 | P2RX7 (0.43) | NPY5RANO1TP53MDM2 | |
| SCHEMBL12756759 | 0.77 | NPY5R (0.41) | NPY5RANO1MEN1KMT2A | |
| SCHEMBL12756657 | 0.75 | DEGS1 (0.44) | GAALMNA | |
| SCHEMBL12756752 | 0.75 | TAS1R3 (0.54) | GAAMEN1KMT2A | |
| SCHEMBL12756545 | 0.73 | ANO1 (0.49) | MAPTANO1LMNATP53MDM2 | |
| SCHEMBL12756734 | 0.72 | NPY5R (0.39) | NPY5RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885MAPT 1478/4885NPY5R 2598/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885MAPT 1478/4885NPY5R 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.